Galderma receives new FDA approval for Restylane Lyft

The US Food and Drug Administration (FDA) has approved Restylane Lyft for cheek augmentation and the correction of age-related mid-face contour deficiencies via small blunt tip cannula in patients over the age of 21.

The approval is the third indication for Restylane Lyft, which is also approved for the nasolabial folds and back of the hands.

In a 16-week multicentre, open-label, prospective study with 60 male and female patients 22 years of age or older, 98.3% of patients showed improvement at week 16 in both the right and left mid-face based on the treating investigator's assessment using the Global Aesthetic Improvement Scale (GAIS). No severe adverse events were reported.  

Alisa Lask, general manager and vice president of the US aesthetic business at Galderma commented, "The FDA approval of Restylane Lyft for mid-face via cannula marks the seventh FDA approval in aesthetics for Galderma in the past four years. We have increased our investment in research and development this year in order to help grow the aesthetic market. Our goal is to continue to offer new solutions and delivery systems to our customers to help drive new patients in to aesthetic offices."